ak127
mAbexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 20, 2021 (NCT05021120)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06530251 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2024 | Akeso Pharmaceuticals, Inc. |
| NCT05951608 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2023 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences, Jiao Tong University |
| NCT05868876 | Phase 1 | Jun 29, 2023 | Akeso Pharmaceuticals, Inc. |
| NCT05393063 | Phase 1 | Jun 30, 2022 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences, Jiao Tong University |
| NCT05021120 | Early Phase 1 (Phase 1) | Oct 20, 2021 | Akeso Pharmaceuticals, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 5 | 5 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Jiao Tong University | Academic/Hospital | 2 | 0 | 2 | 2022 |
3 organizations
Page 1 / 1